Compare · AEMD vs SYK
AEMD vs SYK
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 24359.4x AEMD ($4.7M).
- Over the past year, AEMD is down 99.2% and SYK is down 21.1% - SYK leads by 78.1 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 4 for AEMD).
- SYK has more recent analyst coverage (25 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- Stryker Corporation
- Price
- $2.03+2.53%
- $301.60-1.32%
- Market cap
- $4.7M
- $115.59B
- 1M return
- -10.57%
- +2.47%
- 1Y return
- -99.20%
- -21.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 8
- Recent ratings
- 2
- 25
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest AEMD
- Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Aethlon Medical Inc.
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
- Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
- SEC Form 4 filed by Gikakis Nicolas
- SEC Form 4 filed by Broenniman Edward G
- SEC Form 4 filed by Rossetti Angela
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Gikakis Nicolas
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation